Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-006-9280-9
Annals of Surgical Oncology 14:1772-1779 (2007)
© 2007 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lam, A. K. Y.
Right arrow Articles by Luk, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lam, A. K. Y.
Right arrow Articles by Luk, J. M.

Original Article

Clinicopathological Roles of Alterations of Tumor Suppressor Gene p16 in Papillary Thyroid Carcinoma

Alfred King Yin Lam, MBBS, MD, PhD, FRCPA1, Chung Yau Lo, MBBS, MS, FRCS (Edin.), FACS2, Pauline Leung, BSc2, Brian Hung Hin Lang, MBBS, FRACS2, Wai Fun Chan, MBBS, FRCS (Edin.)2 and John M. Luk, DMedSc2

1 Discipline of Pathology, School of Medicine, Griffith University, PMB 50 Gold Coast Mail Centre, Queensland 9726, Australia
2 Department of Surgery, Faculty of Medicine, University of Hong Kong, Pokfulam Road, Hong Kong, China

Correspondence: Address correspondence and reprint requests to: Alfred King Yin Lam, MBBS, MD, PhD, FRCPA; E-mail: a.lam{at}griffith.edu.au

Background: Alterations of the p16 gene are common in human cancers, but their roles in thyroid cancers have not been clearly defined. The aim of the present study was to investigate the clinicopathological roles of the p16 gene in papillary thyroid carcinoma (PTC).

Methods: p16 gene alterations were investigated in 44 patients with PTC (9 men, 35 women) by immunohistochemistry, reverse transcriptase–polymerase chain reaction and methylation-specific polymerase chain reaction. The findings were correlated with their clinicopathological features.

Results: p16 protein expression, mRNA alterations, and promoter methylation were detected in 89% (n = 39), 77% (n = 33), and 41% (n = 18) of patients with PTC, respectively. There was no marked relationship between p16 protein expression, mRNA alteration, and promoter methylation. In follicular variant of PTC (FVPTC), there was a frequent lack of p16 protein expression and promoter methylation. PTCs showing p16 promoter methylation were often associated with a high AMES (age, metastasis to distant sites, extrathyroidal invasion, size) risk group and advanced pTNM (tumor–lymph node–metastasis) stages.

Conclusions: p16 gene alterations are common and correlate with histological features and biological aggressiveness in PTC, suggesting that they might play an important role in its pathogenesis.

Key Words: p16 • Expression • Methylation • Papillary thyroid carcinoma




This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
A Salajegheh, E B Petcu, R A Smith, and A K-Y Lam
Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists
Postgrad. Med. J., February 1, 2008; 84(988): 78 - 82.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. Melck, H. Masoudi, O. L. Griffith, A. Rajput, G. Wilkins, S. Bugis, S. J. M. Jones, and S. M. Wiseman
Cell Cycle Regulators Show Diagnostic and Prognostic Utility for Differentiated Thyroid Cancer.
Ann. Surg. Oncol., December 1, 2007; 14(12): 3403 - 3411.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society of Surgical Oncology.